Biotransformation and disposition characteristics of HSK7653, a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes

Author:

Bian Yi‐cong12ORCID,Meng Jian3,Hu Tao12,Ma Sheng12,Huang Chen‐rong12,Zhang Feng‐yi4,Wu Qing‐he4,Zhang Hua12,Chen Xiao‐yan3,Miao Li‐yan125

Affiliation:

1. Department of Pharmacy The First Affiliated Hospital of Soochow University Suzhou China

2. Institute for Interdisciplinary Drug Research and Translational Sciences Soochow University Suzhou China

3. Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China

4. Haisco Pharmaceutical Group Company Ltd. Chengdu China

5. National Clinical Research Center for Hematologic Diseases The First Affiliated Hospital of Soochow University Suzhou China

Abstract

AbstractAimTo investigate the metabolism and disposition characteristics of HSK7653 in healthy male Chinese participants.MethodsA single oral dose of 80 μCi (25 mg) [14C]HSK7653 capsules was administered to six healthy participants, and blood, plasma, urine and faeces were collected. Quantitative and qualitative analysis was conducted to investigate the pharmacokinetics, blood‐to‐plasma ratio, mass balance and metabolism of HSK7653.ResultsThe drug was well absorbed and reached a maximum concentration at 1.25 h. The drug‐related components (HSK7653 and its metabolites) were eliminated slowly, with a half‐life (t1/2) of 111 h. Unchanged HSK7653 contributed to more than 97% of the total radioactivity in all plasma samples. The blood‐to‐plasma ratio (0.573‐0.845) indicated that HSK7653 did not tend to distribute into blood cells. At 504 h postdose, up to 95.9% of the dose was excreted, including 79.8% in urine and 16.1% in faeces. Most of the radioactivity (75.5% dose) in excreta was unchanged HSK7653. In addition, nine metabolites were detected in urine and faeces. The most abundant metabolite was M6‐2, a dioxidation product of HSK7653, which accounted for 4.73% and 2.63% of the dose in urine and faeces, respectively. The main metabolic pathways of HSK7653 in vivo included oxidation, pyrrole ring opening and sulphonamide hydrolysation.ConclusionHSK7653 was well absorbed, slightly metabolized and slowly excreted in humans. The high plasma exposure and long t1/2 of HSK7653 may contribute to its long‐lasting efficacy as a long‐acting dipeptidyl peptidase‐4 inhibitor.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3